CN1799601A - Blood lipid-lowering medicine and preparation method thereof - Google Patents
Blood lipid-lowering medicine and preparation method thereof Download PDFInfo
- Publication number
- CN1799601A CN1799601A CN 200510005438 CN200510005438A CN1799601A CN 1799601 A CN1799601 A CN 1799601A CN 200510005438 CN200510005438 CN 200510005438 CN 200510005438 A CN200510005438 A CN 200510005438A CN 1799601 A CN1799601 A CN 1799601A
- Authority
- CN
- China
- Prior art keywords
- extract
- blood lipid
- lowering medicine
- blood
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 239000008280 blood Substances 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 8
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 5
- 229940013618 stevioside Drugs 0.000 claims abstract description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019202 steviosides Nutrition 0.000 claims abstract description 5
- 239000007902 hard capsule Substances 0.000 claims abstract description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 14
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 210000004351 coronary vessel Anatomy 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- 210000001627 cerebral artery Anatomy 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229930003944 flavone Natural products 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 claims 1
- 235000011949 flavones Nutrition 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 235000013619 trace mineral Nutrition 0.000 claims 1
- 239000011573 trace mineral Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 5
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000185386 Thladiantha grosvenorii Species 0.000 abstract 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 abstract 1
- 229940104640 chinese yam extract Drugs 0.000 abstract 1
- 229940072113 onion extract Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013064 chemical raw material Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed is a medicament for lowering blood fat and its preparing process, wherein the medicament comprises Chinese yam extract, root of kudzu vine extract, haw leaves extract, onion extract, Momordica grosvenori extract, stevioside and and magnesium stearate. The medicament can be made into dosage types of powder preparation, tablets or hard capsules.
Description
The present invention relates to a kind of blood lipid-lowering medicine and preparation method thereof, the constituent of this blood lipid-lowering medicine is made up of Rhizoma Dioscoreae extract, Radix Puerariae extract, Folium Crataegi extract, Bulbus Allii Cepae extract, Momordica-Glycosides, stevioside, magnesium stearate.With its preparation powder, tablet, hard capsule dosage form.Have the coronary artery dilator blood vessel, increase coronary artery and cerebral artery blood flow amount, prevent arteriosclerosis and thrombosis, fall effect for blood fat, blood glucose, blood pressure.Curative effect and health function to arteriosclerosis, thrombosis, hypertension, hyperlipidemia, coronary disease pain, angina pectoris, diabetes are obvious.
Knownly be used for arteriosclerosis, thrombosis, hypertension, hyperlipidemia, coronary disease pain, the treatment of diabetes medicine has hundreds of, all be with the synthetic product of chemical raw material, use continuously because of long-term, symptoms such as generation is felt sick, vomiting, headache, anorexia, erythra, perspiration, heating, concurrent hypoglycemia, low blood pressure.And improve the fibrinolytic activity effect and reduce the medicine of lipid effect, but have only antigenicity medicines such as urokinase, streptokinase, antidiabetic medicine has only insulin etc., and can not be oral, have only injection just effectively, certain untoward reaction and side effect are arranged.Its production cost height, technology, equipment complexity.
The objective of the invention is provides a kind of blood lipid-lowering medicine and preparation method thereof in order to solve the defective of above-mentioned existence.
For achieving the above object, the invention provides a kind of blood lipid-lowering medicine and preparation method thereof, this blood lipid-lowering medicine constituent by following percentage by weight is:
Rhizoma Dioscoreae extract 1-20%
Radix Puerariae extract 3-60%
Folium Crataegi extract 0.5-10%
Bulbus Allii Cepae extract 3-60%
Momordica-Glycosides 0.1-0.4%
Stevioside 0.01-0.1%
Magnesium stearate 0.1-4%
Preparation method of the present invention is described below:
1, the preparation of Rhizoma Dioscoreae extract: adopt the temperature more than 100 ℃ to decoct 90 minutes, reduce to room temperature, squeeze and filter, with filtrate concentrate, dry, to be crushed to 200 order fine powders standby.Decocting and using pure water, material-water ratio example is 1: 20.
2, the preparation of Radix Puerariae extract: adopt alcohol extraction twice, under 58-60 ℃ temperature, extracted 120 minutes at every turn, reduce to room temperature, squeeze and filter, merging filtrate, under 58-60 ℃ temperature, vacuum decompression concentrates, and is dry, to be crushed to 200 order fine powders standby.The feed liquid ratio is 1: 20, the ethanol with 95%.
3, the preparation of Folium Crataegi extract: the preparation method that adopts Radix Puerariae extract.
4, the preparation of Bulbus Allii Cepae extract: adopt peeling to squeeze the juice, under 50 ℃ temperature, refine 60 minutes, solution of alcoholized is filtered, vacuum decompression concentrates under 58-60 ℃ temperature, and drying, to be crushed to 200 order fine powders standby.The feed liquid ratio is 1: 10, makes solution of alcoholized with 95% ethanol.
5, the preparation of tablet: by above-mentioned constituent percentage by weight, weighing component, add 5% ethanol mix homogeneously, adopt the rotary tablet machine tabletting.60 ℃ temperature in the electric heating drying baker is dried to the moisture below 5%, reduces to room temperature, carries out irradiation after the packing.
6, the preparation of hard capsule: by above-mentioned constituent percentage by weight, weighing component, mix homogeneously adopts capsule charge mechanism capsule, packing back irradiation.
The blood lipid-lowering medicine that the present invention relates to is characterized by buff, has Herba Alii fistulosi fragrance and fruit to dredge sweet taste.
Pharmacological evaluation shows: the blood lipid-lowering medicine that the present invention relates to has the coronary artery dilator blood vessel, increases coronary artery and cerebral artery blood flow amount, prevents arteriosclerosis and thrombosis, the drug effect of blood fat reducing, blood glucose, blood pressure.Diseases such as arteriosclerosis, thrombotic disease, hypertension, hyperlipidemia, coronary heart disease, angina pectoris, diabetes there are obvious curative effects and health function.
Acute toxicity test shows: the blood lipid-lowering medicine that the present invention relates to, LD50 are the 20000mg/kg body weight, and safety evaluatio is actual non-toxic type, and is without any side effects.
Advantage of the present invention is to adopt the blood lipid-lowering medicine of natural plants preparation, has enlarged the scope of its application, can make full use of artificial growth and wild resource, and its resource is sufficient and guaranteed.
Another advantage of the present invention is to utilize natural plant resource, has reduced cost of material, preparation extract yield height, and production technology is simple, is fit to suitability for industrialized production.The most outstanding advantage of the present invention is to provide a kind of new medicine for the control cardiovascular and cerebrovascular disease.
Embodiment:
Get Rhizoma Dioscoreae extract 80g, Radix Puerariae extract 240g, Folium Crataegi extract 400g, Bulbus Allii Cepae extract 6000g, Momordica-Glycosides 0.2g, stevioside 0.1g, stearic enzyme magnesium 400g adds edible ethanol 100ml, mix homogeneously.Employing is tabletting in rotary tablet machine, and 8000 in preparation tablet is the 1.25g/ sheet.Carry out drying and be placed in the electric heating drying baker 60 ℃, and ethanol is volatilized fully, be finished product, standby with PP plastic bottle splendid attire.Give 40 people's lab-gowns with 30 days, 3 times for each person every day, each 2.40 people are overt diabetes companion hyperlipemia, and inactive other medicines 30 days.Through the repeated detection fasting plasma lipid, T-CHOL (TO) 〉=6.30mmol/L, triglyceride (TO) 〉=1.98mmol/L, high density lipoprotein (HDL)≤1.10mmol/L.Experimentize and take front and back self contrast, carry out curative effect more relatively.Lab-gown was with 30 days, and testing crew TC, TO significantly descend, and HDL obviously raises (P＜0.001), and the TC rate of descent is 25.7-46.5%.Individual curative effect difference, there have 3 people TO to descend to be apparent in view, and the TO rate of descent is respectively 31.5%, 49%, 58.1% after taking medicine 30 days.Wherein 21 people are the hyperpietic, and high TO patient carries out the medicine examination, obtains good result, and the blood pressure lowering rate is 82.5%; The blood pressure drops amplitude, systolic pressure decline 3.10kpa, diastolic pressure on average reduces 2.7kpa, and its hypotensive effect is remarkable, and with blood vessel dilating, it is relevant to reduce Peripheral resistance.Diabetics to the examination clothes is also obtained good lipid-lowering effect, the TO 1.15mmol/L that on average descends has significantly the effect of TC and rising HDL down, and TC on average reduces 3.07mmol/L, the HDL 0.84mmol/L that on average raises, its curative effect is higher than vitamin E (P＜0.05-0.01).Clinical trial is the result show: the blood lipid-lowering medicine that the present invention relates to is tangible natural blood lipid-lowering medicine of a kind of curative effect and health product.
The above embodiment of the present invention only is to be exemplifying that explanation is clearly done, and is not qualification to embodiment of the present invention, to the fabricating technology scheme in affiliated field.Obviously can make other multi-form variation on the basis of the above description, the product of preparation difformity and dosage form need not also can't give all embodiments exhaustive here.And the product of these variations and different types thereof still is among protection scope of the present invention.
Claims (3)
1. blood lipid-lowering medicine, it is characterized in that its constituent percentage by weight is: Rhizoma Dioscoreae extract 1-20%, Radix Puerariae extract 3-60%, Folium Crataegi extract 0.5-10%, Bulbus Allii Cepae extract 3-60%, Momordica-Glycosides 0.1-4%, stevioside 0.01-0.1%, magnesium stearate 0.1-4%.
2. according to claim 1, the blood lipid-lowering medicine that mixes is a flour, moisture Control in 5%, plant total flavones 20-25%, aminoacid 6.5-7.3%, various trace elements 3-3.5%.
3. according to claim 1, as to mix blood lipid-lowering medicine is prepared into tablet, hard capsule dosage form.Have the coronary artery dilator blood vessel, increase coronary artery and cerebral artery blood flow amount, prevent arteriosclerosis and thrombotic effect.Curative effect and health function to arteriosclerosis, thrombosis, hypertension, hyperlipidemia, coronary heart disease, angina pectoris, diabetes are obvious.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510005438XA CN100509031C (en) | 2005-01-05 | 2005-01-05 | Blood lipid-lowering medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510005438XA CN100509031C (en) | 2005-01-05 | 2005-01-05 | Blood lipid-lowering medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1799601A true CN1799601A (en) | 2006-07-12 |
| CN100509031C CN100509031C (en) | 2009-07-08 |
Family
ID=36809960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510005438XA Expired - Fee Related CN100509031C (en) | 2005-01-05 | 2005-01-05 | Blood lipid-lowering medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100509031C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101932240A (en) * | 2007-10-10 | 2010-12-29 | 环球有机物有限责任公司 | Anti-glycation methods and compositions |
| CN103566150A (en) * | 2013-10-10 | 2014-02-12 | 北京昊源康科技有限公司 | Medicine and food homologous food composition with blood fat reducing function as well as application thereof |
| CN105249321A (en) * | 2015-09-01 | 2016-01-20 | 上海医药工业研究院 | Composition and preparation method and application thereof |
| CN115813871A (en) * | 2022-12-23 | 2023-03-21 | 宝利康生物科技(天津)有限公司 | Blood pressure reducing tablet candy and application method thereof |
-
2005
- 2005-01-05 CN CNB200510005438XA patent/CN100509031C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101932240A (en) * | 2007-10-10 | 2010-12-29 | 环球有机物有限责任公司 | Anti-glycation methods and compositions |
| CN103566150A (en) * | 2013-10-10 | 2014-02-12 | 北京昊源康科技有限公司 | Medicine and food homologous food composition with blood fat reducing function as well as application thereof |
| CN103566150B (en) * | 2013-10-10 | 2016-01-06 | 北京昊源康科技有限公司 | A kind of compositions and application thereof with the integration of edible and medicinal herbs food of effect for reducing blood fat |
| CN105249321A (en) * | 2015-09-01 | 2016-01-20 | 上海医药工业研究院 | Composition and preparation method and application thereof |
| CN115813871A (en) * | 2022-12-23 | 2023-03-21 | 宝利康生物科技(天津)有限公司 | Blood pressure reducing tablet candy and application method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100509031C (en) | 2009-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102362881A (en) | Method for preparing ginkgo and American ginseng preparation | |
| CN101693062B (en) | Health-care product for reducing pressure and sugar and eliminating fat | |
| CN102293868B (en) | Application of total flavonoids of lilac daphne root in preparation of medicament for reducing blood sugar | |
| CN106072527B (en) | A kind of natto composition of toxin-expelling and face nourishing and preparation method thereof | |
| CN101129790A (en) | Compound hippophae rhamnoides lozenge method of producing the same | |
| CN101953918B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases | |
| CN108042716A (en) | A kind of traditional Chinese medicine preparation product of auxiliary hyperglycemic | |
| CN100509031C (en) | Blood lipid-lowering medicine | |
| CN106072635A (en) | A kind of preparation method of Radix Ginseng buccal tablet | |
| CN101816414B (en) | Application of sunflower leaves for preparing foods and health-care foods for reducing blood pressure in auxiliary way | |
| CN100496520C (en) | Chinese-medicinal extract for treating cardiovascular disease, its preparation and use | |
| CN100493578C (en) | Chinese medicine composition for treating thin body and delicate constitution, and preparing method | |
| CN109717426A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN1330353C (en) | Chinese traditional medicine for adjusting contents of blood sugar and blood fat, and preparation method | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN106309736B (en) | Anti-fatigue Chinese medicinal composition and its preparation method and application | |
| CN104336287B (en) | Syringa pubescens sugar-free health-care candy with blood pressure lowering effect and preparation method thereof | |
| CN1123097A (en) | "Jiangtanghu" and its production technology | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN1292272A (en) | Medicine for curing diabetes and its preparation method | |
| CN106728373A (en) | Poria cocos glossy ganoderma and honey oral liquid | |
| CN101623325B (en) | Ziziphora clinopodioides Lam. total flavonoid extract and production method thereof and application thereof in cardiovascular drug | |
| CN105055979A (en) | Traditional Chinese medicine compounded composition and lozenge for preventing and curing diabetes and preparation method thereof | |
| CN1297277C (en) | Laminaran granule and its preparation technology | |
| CN1813709B (en) | Safflower yellow dropping pill, and its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Cao Zhengan Document name: Notice of publication of application for patent for invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhuhai Enzhaoer Biological Technology Co., Ltd. Document name: Notification of the application for patent for invention to go through the substantive examination procedure Addressee: Zhuhai Enzhaoer Biological Technology Co., Ltd. Document name: Notice of conformity |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20090220 Address after: Jiangsu Province, Wuxi new area, industrial park five B14-1 plots (located at the intersection of Sun Anlu and Shannon Road) post encoding: 214000 Applicant after: Jiangsu AnJi Biotechology Co., Ltd. Address before: Guangdong province Zhuhai city Xiangzhou District Jida Bailian Road No. 49 Building 9 post encoding: 519015 Applicant before: Zhuhai Enzhaoer Biological Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU ANJIER BIOLOGY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHUHAI ENSHAOER BIOLOGICAL SCIENCE AND TECHNOLOGY LTD. Effective date: 20090220 |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Jiangsu AnJi Biotechology Co., Ltd. Document name: Review of business letter |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090708 Termination date: 20100205 |